Mesothelioma Research Clinic Web Directory, and Resources |
||||||||||||||||||||
Mesothelioma Research Clinic Resources
This site contains resources and articles for you to use when you are looking for information about mesothelioma research clinic. This site has articles, links to mesothelioma research clinic, information and news. In the future we will have reviews of products that will help you make your decision easier with mesothelioma research clinic, so you can save time
Featured Mesothelioma Research Clinic Article
Mesothelioma Standard Treatment Options II By: Govt Standard treatment options:
The safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-n aive patients with malignant mesothelioma who were not eligible for curative surgery was demonstrated in a large phase III randomized trial. This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously every 21 days). A total of 456 patients were enrolled: 226 patients received pemetrexed plus cisplatin and 222 patients received cisplatin alone; 8 patients did not receive therapy. After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects. Folic acid (350-1,000 µg orally) was given daily, beginning 1 to 3 weeks before the first chemotherapy dose and continuing daily until 1 to 3 weeks after treatment ended. A vi tamin B12 injection (1,000 µg intramuscularly ) was administered 1 to 3 weeks before the first chemotherapy dose and was repeated approximately every 9 weeks until treatment ended. Dexamethasone (4 mg) or an equivalent corticosteroid was administered orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose. In an analysis of all patients who were randomized and treated, the combination of pemetrexed and cisplatin was associated with a statistically significant improvement in survival compared with cisplatin alone; the median survivals were 1 2.1 versus 9.3 months, respectively (P=.020). The hazard ratio for death of patients in the pemetrexed plus cisplatin arm versus those in the control arm was 0.77. Median time to progression was significantly longer in the pemetrexed plus cisplatin arm (5.7 months vs 3.9 months, P=.001). This sup....[MORE]
Sponsored Mesothelioma Research Clinic ResourcesThese are our featured resources and providers for mesothelioma research clinic. Feel free to check them out if you are looking for resources and articles for you to use. This list includes sites with articles, mesothelioma research clinic resources, information and news. Additional Mesothelioma Research Clinic Resources
|